Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
(Posted: 03/18/2009) - Six annual screenings for prostate cancer led to more diagnoses of the disease, but no fewer prostate cancer deaths, according to a major new report from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, a 17-year project of the NCI. The PLCO was designed to provide answers about the effectiveness of prostate cancer screening.
Radiation Therapy Helps Prevent DCIS Recurrence After Breast-Conserving Surgery
(Posted: 03/10/2009) - The addition of radiation therapy to breast-conserving surgery halves the risk of a tumor recurrence compared with surgery alone in women with noninvasive breast tumors, according to a pooled analysis of trial results published January 21, 2009, by the Cochrane Reviews.
Double Transplantation of One's Own Stem Cells Is Not Warranted for Multiple Myeloma
(Posted: 02/24/2009) - The addition of a second hematopoietic stem cell transplant procedure using one's own blood cells does not appear warranted in multiple myeloma, according to the Jan. 21, 2009, Journal of the National Cancer Institute.
Removal of Ovaries and Fallopian Tubes Cuts Cancer Risk for BRCA1/2 Carriers
(Posted: 02/24/2009) - Surgery that removes the ovaries and fallopian tubes is one of the most effective ways to decrease a woman's risk of breast and gynecologic cancer if she carries a BRCA1 or BRCA2 gene mutation, according to the Jan. 21, 2009, Journal of the National Cancer Institute.
Combining Targeted Drugs Is Worse in Colorectal Cancer
(Posted: 02/24/2009) - A clinical trial testing chemotherapy combined with bevacizumab (Avastin) and cetuximab (Erbitux), and comparing this with chemotherapy and bevacizumab alone, found that the addition of cetuximab was actually worse for patients, according to the Feb. 5, 2009, New England Journal of Medicine.